Bristol Myers Squibb (BMY) Operating Margin (2009 - 2026)

Bristol Myers Squibb has disclosed Operating Margin across 18 years of filings, most recently posting 1.58% for Q1 2026.

• In Q1 2026, Operating Margin fell 103.0% year-over-year to 1.58%; the TTM figure through Mar 2026 stood at 9.75% (up 696.0% YoY), while the FY2025 annual figure was 9.56%, up 3671.0% from the prior year.
• Operating Margin climbed to 1.58% in Q1 2026, from 21.01% in the prior quarter.
• Over the last five years, Operating Margin for BMY reached as high as 1.8% in Q1 2023 and fell as low as 121.77% in Q1 2024.
• The 5-year median for Operating Margin is 6.73% (2022), against an average of 15.65%.
• Annual changes were most pronounced in 2024 — Operating Margin plunged 12357 bps — and 2025, when it surged 12122 bps.
• A 5-year view of Operating Margin shows it stood at 6.44% in 2022, then slumped by 45 bps to 9.33% in 2023, then tumbled by 303 bps to 37.57% in 2024, then surged by 44 bps to 21.01% in 2025, then soared by 92 bps to 1.58% in 2026.
• According to Business Quant data, Operating Margin over the past three periods registered 1.58%, 21.01%, and 2.63% for Q1 2026, Q4 2025, and Q3 2025 respectively.